Immuneering Corporation

NASDAQ•IMRX

執行長: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-07-30

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

聯絡資訊

245 Main Street, Second Floor, Cambridge, MA, 02142, United States

617-500-8080

immuneering.com

市值

$180.79M

本益比 (TTM)

-3.2

17.8

股息率

52周最高

$10.08

52周最低

$1.10

52周範圍

43%

排名44Top 53.8%

3.7

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 3.7 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q3 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.38-22.45%

近4季度走勢

自由現金流

-$11.98M-11.08%

近4季度走勢

2025 Q3 財報亮點

核心亮點

Financing Bolsters Cash Position Net cash provided by financing activities reached $226.9M, increasing total cash equivalents to $227.6M as of September 30, 2025.

Atebimetinib Clinical Data Lead candidate atebimetinib showed 86% overall survival and 53% progression free survival in updated interim data.

R&D Spending Prioritization Nine-month Research and development expenses slightly decreased 0.9% to $32.8M, prioritizing atebimetinib development.

Equity Issuance Significant Class A common stock issued increased shares outstanding to 63.5M from 31.1M since December 31, 2024.

關注風險

Clinical Stage Operations Company is clinical-stage oncology firm; has no approved products, making future success difficult to evaluate or predict.

Continued Operating Losses Incurred significant net losses for several years; expects recurring losses for foreseeable future, delaying profitability.

Substantial Capital Requirement Requires substantial additional capital to finance operations; inability to raise funds may force program delays or elimination.

Regulatory Approval Uncertainty FDA approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for product candidates.

未來展望

Pivotal Trial Dosing Planned Expects to dose first patient in pivotal Phase 3 trial for atebimetinib combination by mid-2026, pending regulatory feedback.

Focus Resources on Lead Made strategic decision to pause internal advancement of IMM-6-415, focusing resources on atebimetinib development.

Cash Runway Extended Current cash and equivalents estimated sufficient to fund operating expenses and capital requirements into 2029.

Future Regulatory Feedback Anticipates receiving regulatory feedback on pivotal Phase 3 clinical trial plans in the fourth quarter of 2025.

同行對比

營業收入 (TTM)

ARCT

$78.24M

-43.5%

ENTA

$66.98M

+0.6%

CDXS

$52.93M

-17.9%

毛利率 (最新季度)

ARCT

408.3%

-19.5pp

ENTA

100.0%

+0.0pp

ASMB

100.0%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
SLS	$752.09M	-22.1	-95.2%	1.2%
TRDA	$444.11M	-3.3	-39.8%	13.5%
ASMB	$437.58M	-5.5	-59.0%	1.1%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年3月19日

每股收益:-$0.31

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料